5 Stocks to Sell Now According to Orkun Kilic’s Berry Street Capital

In this piece, we take a look at the five stocks to sell now according to Orkun Kilic’s Berry Street Capital. For more stocks, take a look at 10 Stocks to Sell Now According to Orkun Kilic’s Berry Street Capital.

5. argenx SE (NASDAQ:ARGX)

Berry Street Capital’s Stake Value In Q1 2022: $7.8 million

Percentage of Berry Street Capital’s 13F Portfolio In Q1 2022: 0.89%

Number of Hedge Fund Holders: 35

argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company that focuses on developing treatments for autoimmune diseases. Some of the diseases that its treatments target include neuropathy, myopathy, cancer, and airway inflammation. The firm is headquartered in Breda, the Netherlands.

argenx SE (NASDAQ:ARGX) has been performing well when it comes to its drug that treats muscle weakening. This drug is called Vyvgart, and the company’s latest quarter revealed that it sequentially grew sales by $21 million to stand at $75 million as the second quarter ended. Piper Sandler raised the company’s share price target to $450 from 465 in August 2022, sharing that Vyvgart’s performance was impressive, with neurologists expressing confidence in the drug.

Mr. Kilic’s first quarter of 2022 stake in argenx SE (NASDAQ:ARGX) was worth $7.8 million and it came in the form of 25,000 shares. During the second quarter, this entire stake was sold by Kilic’s fund.

argenx SE (NASDAQ:ARGX)’s largest investor is Kurt Von Emster’s VenBio Select Advisor which owns 1.2 million shares that are worth $479 million.